Wednesday, 21 Aug 2019

You are here

Presenting Features of Early SLE

What clinical features best identify early systemic lupus erythematosus (SLE) patients from mimics?  A multicenter, multinational study aimed to evaluate manifestations at disease onset and to compare early SLE manifestations to those of diseases mimicking SLE.

Baseline, presenting data from academic lupus centers in Asia, Europe, North America, and South America on patients presenting for possible SLE with a symptom duration of <1 year. The diagnosis of SLE was based on the 1997 American College of Rheumatology (ACR) SLE classification criteria and the 2012 Systemic Lupus International Collaborating Clinics (SLICC) SLE classification criteria. 

A cohort comparison of 389 patients with early SLE and 227 patients with SLE‐mimics demonstrated the following features that distinguished SLE from other conditions.

 SLEMimicsp value
Unexplained Fever34.5%13.7%<0.001
Raynauds22.1%48.5%<0.001
Sicca Sx4.4%34.4%<0.001
Dysphagia0.3%6.2%<0.001
Fatigue28.3%37%0.024

While unexplained fever better identified early SLE, the presence of Raynauds, Sicca complex, dysphagia and fatigue were more apt to indication an SLE‐mimicking condition.

Lupus criteria features were affirmed as reliable distinguishing features, including malar rash (50% vs 6%), photosensitivity (32% vs 19%), oral ulcers (22% vs 5%), alopecia (31% vs 12%), pleuritis ( 22% vs 3%), etc.

Similarly, double‐stranded DNA and anti–β2‐glycoprotein I antibodies, positive Coombs’ test results, autoimmune hemolytic anemia, hypocomplementemia, and leukopenia were more common in early SLE than in SLE‐mimicking conditions.

. Fewer patients with early SLE were not identified as having early SLE with use of the SLICC criteria compared to the ACR criteria (16.5% versus 33.9%), but the ACR criteria demonstrated higher specificity than the SLICC criteria (91.6% versus 82.4%).

This cohort study affirms the clinical manifestations that help distinguish early SLE from SLE‐mimicking conditions. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

With Autoimmunity, Checkpoint Inhibitors Can Be Used

Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.

New EULAR/ACR Classification Criteria for SLE

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.

Sjogren's Syndrome at Risk for Psychiatric Disorders

A population-based claims study from Taiwan shows significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder in patients with primary Sjögren’s syndrome (pSS). 

Abatacept Disappoints in Systemic Sclerosis

A 12‐month, Phase 2 trial has shown that subcutaneous abatacept was well tolerated in patients with diffuse cutaneous systemic sclerosis (dcSSc), but failed to significantly change the skin outcomes as measured by the change in modified Rodnan skin score (mRSS)

FDA AAC Splits Vote in Favor of Nintedanib for Scleroderma Interstitial Lung Disease

The FDA convened Arthritis Advisory Committee to consider nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) and voted 10-7 in favor of approving the drug for this new indication.